Technology | February 19, 2009

Bard Receives FDA Approval for the LifeStent Peripheral Stent



February 19, 2009 - C. R. Bard Inc. this week said it received pre-market approval (PMA) from the FDA to market the LifeStent FlexStar and FlexStar XL Vascular Stent Systems, which are approved for the treatment of occlusive disease in native superficial femoral arteries (SFA) and proximal popliteal arteries.


Two-year clinical data on the LifeStent vascular stent demonstrated a freedom from target lesion revascularization rate of 78 percent vs. 42 percent (p

“The long-term data recently presented are important because they demonstrate the sustained performance of the LifeStent vascular stent,” said Dr. Barry Katzen, M.D., founder and medical director of Baptist Cardiac and Vascular Institute and co-principal investigator of the LifeStent RESILIENT trial. “Of particular significance to clinicians and patients is the approval of the 170 mm stent, the longest commercially available in the U.S. Henceforth, long and diffuse lesions presenting in the SFA can be effectively treated with a single stent, which should help improve both clinical outcomes and procedural costs.”


Bard said approval of the LifeStent positions it as the only company offering a stent indicated for the treatment of SFA and proximal popliteal disease in the U.S.


For more information: www.crbard.com


Related Content

Sunshine Heart, C-Pulse, circulatory support system, update
News | Heart Failure| August 03, 2015
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
UNC, biomarkers, severe heart disease, fructosamine, LDL cholesterol, Nichols
News | Cardiac Diagnostics| July 21, 2015
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
Overlay Init